Related Experiment Videos
Can severe vincristine neurotoxicity be prevented?
Cancer Chemotherapy and Pharmacology
|January 1, 1982
Summary
Vincristine neurotoxicity is linked to individual doses, not just cumulative ones. Elevated serum alkaline phosphatase can predict severe neurotoxicity, even without other liver dysfunction signs.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Vincristine neurotoxicity is typically dose-dependent and linked to cumulative exposure.
- Liver dysfunction is a known factor for reducing vincristine dosage.
- Predictive markers for severe neurotoxicity are crucial for patient management.
Purpose of the Study:
- To investigate the relationship between individual vincristine doses, serum alkaline phosphatase levels, and neurotoxicity.
- To determine if serum alkaline phosphatase can predict severe neurotoxicity in vincristine treatment.
- To explore the impact of elevated serum alkaline phosphatase on vincristine pharmacokinetics.
Main Methods:
- Studied vincristine exposure in 27 subjects post-IV injection.
- Measured the area under the vincristine plasma concentration-time curve (AUC0-infinity).
- Correlated AUC0-infinity with neurotoxicity severity and serum alkaline phosphatase levels.
Main Results:
- A significant relationship was found between AUC0-infinity and the degree of neurotoxicity.
- Elevated serum alkaline phosphatase correlated with higher AUC0-infinity, indicating impaired drug elimination.
- Reducing vincristine dose in patients with elevated serum alkaline phosphatase lowered AUC0-infinity and neurotoxicity.
Conclusions:
- Neurotoxicity from vincristine is related to individual doses and pharmacokinetic profiles.
- Elevated serum alkaline phosphatase is a potential predictor of severe vincristine-induced neurotoxicity.
- Dosage adjustments based on serum alkaline phosphatase levels may mitigate neurotoxicity risk.